ALBANY

Frisch angekündigte Übernahmen im Pharmasektor haben die US-Börsen zu Wochenbeginn deutlich angetrieben. Auch Spekulationen über Maßnahmen der chinesischen Regierung zur Stimulierung der dortigen Wirtschaft stützten am Montag die Kurse, sagten Börsianer. http://www.ariva.de/news/...gungen-treiben-die-Wall-Street-an-5324942  

auf 17 955,56 Punkte an. In der vergangenen Woche hatte der US-Leitindex noch 2,29 Prozent verloren. Für den marktbreiten S&P-500-Index ging es am Montag um 0,90 Prozent auf 2079,61 Punkte nach oben. An der Nasdaq stieg der technologielastige Auswahlindex Nasdaq 100 (Nasdaq 100) um 0,72 Prozent auf 4363,98 Punkte. http://www.ariva.de/news/...gungen-treiben-die-Wall-Street-an-5324942
 

Wieso Helm ???
In der Gummizelle braucht man doch keinen, alles schön weich u. gepolstert dort ...
COOL
Frag mal das Burani ...
GRINS  

http://www.ariva.de/news/...ll-U-K-API-Manufacturing-Facility-5329018 GrB  

AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
14:00 01.05.15

PR Newswire

ALBANY, New York, May 1, 2015

ALBANY, New York, May 1, 2015 /PRNewswire/ -- Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, AMRI's President and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13, 2015 at 4:20 p.m. ET.

A live audio webcast of the presentation can be accessed at AMRI's Investor Relations web site at http://ir.amriglobal.com/events.cfm?CalendarID=2

The webcast will be archived for 90 days following the live presentation.
http://www.ariva.de/news/...Lynch-2015-Health-Care-Conference-5354414  

http://www.ariva.de/news/...ounces-First-Quarter-2015-Results-5356951 GrB  

http://www.ariva.de/news/...borative-Agreement-in-Buffalo-N-Y-5382307 GrB  

AMRI and PerkinElmer Announce Drug Discovery Collaboration as part of the Buffalo Medical Innovation and Commercialization Hub
13:05 17.06.15

PR Newswire

BUFFALO, New York, June 17, 2015
http://www.ariva.de/news/...ovation-and-Commercialization-Hub-5396922  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  02.07.15     19,83     20,09§19,77 19,92 $ 258.079 4,99 M

GrB  

13:35 16.07.15

PR Newswire

ALBANY, N.Y., July 16, 2015

ALBANY, N.Y., July 16, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has acquired all the outstanding shares of Gadea Pharmaceutical Group, a privately-held company located in Valladolid, Spain, specializing in technically complex active pharmaceutical ingredients (APIs) and finished drug product. The purchase price was $174 million, including the issuance of 2.2 million shares of common stock to Gadea's owners, valued at $43.8 million, with the balance paid in cash and through the assumption of existing debt. http://www.ariva.de/news/...quires-Gadea-Pharmaceutical-Group-5425080  

14:05 21.07.15

PR Newswire

ALBANY, N.Y., July 21, 2015

ALBANY, N.Y., July 21, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced it will issue second quarter 2015 financial results before the opening of the market on Tuesday, August 4, 2015. Following the release of its results, the company will host a conference call and simultaneous audio webcast at 8:30 a.m. ET.

The conference call can be accessed by dialing (866) 208-5728 (domestic calls) or (224) 633-1279 (international calls) at 8:20 a.m. ET and entering passcode 69698467. A live webcast with slides will also be available and can be accessed on the company's website at www.amriglobal.com. A replay of the conference call can be accessed for 24 hours at (855) 859-2056 (domestic calls) or (404) 537-3406 (international calls) and entering passcode 69698467. Replays of the webcast can also be accessed for up to 90 days after the call via the investor area of the company's website at http://ir.amriglobal.com. http://www.ariva.de/news/...ounce-Second-Quarter-2015-Results-5429432  

Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Drug Product Manufacturing supports development through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal). http://www.ariva.de/news/...ounce-Second-Quarter-2015-Results-5429432
 

:::::::::::::::: 20,60 $ +3,21% +0,64 $
In Euro: 18,418 € | Nasdaq, 28.08.15 ,GrB  

http://www.ariva.de/news/...corporation-licenses-biosynthetic-5789171 GrB  

Albany Molecular Research Inc.
Mittwoch, 10.08.2016 18:00 von PR Newswire

       
PR Newswire

WAYNE, Pa., Aug. 10, 2016

WAYNE, Pa., Aug. 10, 2016 /PRNewswire/ -- Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Albany Molecular Research, Inc. ("Albany Molecular" or the "Company") (NASDAQ: AMRI). http://www.ariva.de/news/...announces-investigation-of-albany-5843531  

like to learn more about this class action or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/amri. You may also email Mr. Maniskas at rmaniskas@rmclasslaw.com.  http://www.ariva.de/news/...announces-investigation-of-albany-5843531

 

manufacturing company that provides integrated drug discovery, development and manufacturing services primarily in the United States, Europe and Asia. The complaint alleges that throughout the Class Period defendants misrepresented and/or failed to disclose material adverse facts about the Company's operations, financial performance and prospects, including the Company's financial guidance and operations at its OsoBio facility.

On November 5, 2014, the Company announced weak financial and operating results for third quarter 2014, including an $8.6 million loss in the quarter. The Company attributed the weak third quarter to a "confluence of a business interruption event at our OsoBio facility, together with lower Discovery and API revenue." In addition, the Company disclosed a "weather-related power interruption at our OsoBio facility in Albuquerque took the facility offline for a period of time, contributing to the loss of finished product and the need to remediate one of the suites at the facility." Following this news, Albany Molecular stock declined nearly 27%, or $6.08 per share, to close at $16.59 per share on November 5, 2014.

Ryan & Maniskas, LLP is a national shareholder litigation firm.  Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide. http://www.ariva.de/news/...announces-investigation-of-albany-5843531  

Healthcare Conference
Dienstag, 13.12.2016 14:05 von PR Newswire  http://www.ariva.de/news/...35th-annual-j-p-morgan-healthcare-5979214  

Conversion of Inventor's Intellectual Property Rights by Albany Molecular Research Inc. (AMRI)
Dienstag, 12.09.2017 13:35 von PR Newswire

     
PR Newswire http://www.ariva.de/news/...ion-alleging-fraud-and-conversion-6463694